AMENDMENTS TO THE CLAIMS

In the claims, please cancel claim 17 and amend claims 14, 16, and 23 as follows:

- 1-13. (canceled)
- 14. (currently amended) A process for delivery of a polynucleotide to a cell comprising:
 - a) forming a complex consisting of a polynucleotide and a primary amine-containing polycationic molecule;
 - b) adding a chelator capable of forming a non-covalent coordinate bond with a primary amine to the complex of a) to form a new complex wherein the chelator forms a non-covalent coordinate bond with the primary amine on the primary amine-containing polycationic molecule; and,
 - c) delivering the new complex to the cell.
- 15. (previously presented) The process of claim 14 wherein the chelator consists of a crown ether.
- 16. (currently amended) The process of claim 14 wherein the primary amine-containing polycationic molecule is a polyamine.
- 17. (canceled)
- 18. (previously presented) The process of claim 14 wherein the chelator consists of a polychelator.
- 19. (previously presented) The process of claim 18 wherein the polychelator consists of a polyanion.
- 20. (previously presented) The process of claim 19 wherein the polyanion recharges the complex to give the complex a negative surface charge.
- 21. (previously presented) The process of claim 18 wherein the polychelator consists of a polycation.
- 22. (previously presented) The process of claim 14 wherein the chelator is covalently linked to a compound selected from the list consisting of: a cell targeting signal, a releasing signal, and a hydrophobic group.
- 23. (currently amended) The process of claim 14 wherein the primary amine-containing polycationic molecule is selected from the list consisting of: a cell receptor signal, a releasing signal, a hydrophobic group and a steric stabilizer.
- 24. (previously presented) The process of claim 14 wherein the polynucleotide is expressible.

- 25. (previously presented) The process of claim 24 wherein the polynucleotide expresses a therapeutic gene.
- 26. (previously presented) The process of claim 14 wherein the cell consists of an in vivo mammalian cell.